Business
Dr. Fahar Merchant acquires shares of Medicenna
On December 15, 2025, Fahar Merchant, President and Chief Executive Officer of Medicenna Therapeutics Corp. ("Medicenna"), purchased an aggregate of 32,000 common shares of Medicenna (the "Shares") through the facilities of the Toronto Stock Exchange at a price of $1.11 per Share, for an aggregate consideration of $35,520 (the "Transaction").
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"TORONTO, Dec. 15, 2025 /CNW/ - On December 15, 2025, Fahar Merchant, President and Chief Executive Officer of Medicenna Therapeutics Corp. ("Medicenna"), purchased an aggregate of 32,000 common shares of Medicenna (the "Shares") through the facilities of the Toronto Stock Exchange at a price of $1.11 per Share, for an aggregate consideration of $35,520 (the "Transaction").","length":425,"tagName":"p"},{"type":"text","content":"Prior to the Transaction, (i) Dr. Merchant beneficially owned an aggregate of 5,808,802 Shares and options ("Options") to purchase an aggregate of 2,980,786 Shares; (ii) Ms. Rosemina Merchant, a joint actor with Dr. Merchant, beneficially owned 5,596,490 Shares and Options to purchase 1,812,069 Shares; and (iii) Aries Biologics Inc. ("Aries") an entity jointly-owned by Dr. Merchant and Ms. Merchant, beneficially owned an aggregate of 5,500,000 Shares. Together, Dr. Merchant and Ms. Merchant beneficially owned, directly and through Aries, an aggregate of 16,905,292 Shares and 4,792,855 Options, representing 20.27% of the currently issued and outstanding Shares on a non-diluted basis, and 24.60% of the currently issued and outstanding Shares on a partially-diluted basis, assuming exercise of the Options held by Dr. Merchant and Ms. Merchant only. Due to dilution caused by the issuance of additional Shares by Medicenna from time to time, the proportionate holdings of Dr. Merchant, Ms. Merchant and Aries had decreased from those disclosed in an early warning report filed by Dr. Merchant on February 22, 2023, at which time the aggregate of 16,071,400 Shares, 3,142,855 Options and 200,000 common share purchase warrants (the "Warrants") beneficially owned by Dr. Merchant and Ms. Merchant, directly and through Aries, represented 23.10% of the then issued and outstanding Shares on a partially-diluted basis, and 26.60% of the then issued and outstanding Shares on a partially-diluted basis, assuming exercise of the Options and Warrants held by Dr. Merchant and Ms. Merchant only.","length":1709,"tagName":"p"},{"type":"text","content":"Following the Transaction, (i) Dr. Merchant beneficially owns an aggregate of 5,840,802 Shares and Options t...